1/31/23
Amgen, a biotechnology company, has announced the availability of its biosimilar drug AMJEVITA™ (adalimumab-atto) in the United States. This drug is a biosimilar to Humira®* (adalimumab) and was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA) in 2016. AMJEVITA is now the first U.S. biosimilar to Humira® and is expected to reduce the cost of treating spondyloarthritis and other serious inflammatory diseases.
According to Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen, “With today’s announcement, AMJEVITA is the first U.S. biosimilar to Humira®, a medicine used by more than a million patients living with certain serious inflammatory diseases. With our track record of developing and manufacturing biologics and decades of experience in inflammation, Amgen is uniquely equipped to supply this biosimilar medicine while reducing costs.”
The Arthritis Foundation’s CEO, Steven Taylor, said, “Biosimilars are extensively studied, FDA-approved treatments that have the potential to reduce costs to the healthcare system. AMJEVITA provides another treatment option for patients and their doctors.”
AMJEVITA will be available in prefilled syringe and autoinjector presentations to support dosing in each of the approved indications. It is also citrate-free, like Humira’s citrate-free formulation that is associated with less pain at the injection site. The drug is available in two options at a list price 55% and 5% below the current Humira list price, and Amgen aims to provide broad access to patients by offering both options to health plans and pharmacy benefit managers.
Amgen has 11 biosimilar medicines currently in the market or under development, with five already FDA-approved in the U.S. and three approved in the European Union. The company also offers patient support through AMJEVITA SupportPlus, including financial support information and educational resources, which can be found on their website at AMJEVITA.com.
For patients with spondyloarthritis and other serious inflammatory diseases, the availability of AMJEVITA as a biosimilar to Humira provides another treatment option and the potential for reduced healthcare costs.
References:
Input your search keywords and press Enter.
